Carcinoma, Non-Small-Cell Lung
Conditions
Brief summary
The main aim of this study is to evaluate the safety and tolerability of afatinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring Epidermal Growth Factor Receptor (EGFR) mutation(s) and have never been treated with an EGFR-Tyrosine Kinase Inhibitor (TKI)
Interventions
DRUGAfatinib
40, 30, or 20mg tablets taken once daily, dosage depending on tolerability
Sponsors
Boehringer Ingelheim
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) 2. Epidermal Growth Factor Receptor (EGFR) mutation-positive results per the institution's testing methodology 3. Male or female patients age \>=18 years 4. Adequate organ function, defined as all of the following: 1. Absolute neutrophil count (ANC) \>1500/mm3 2. Platelet count\>75,000/mm3 3. Serum creatinine\<1.5 times of the upper limit of (institutional) normal and/or creatinine clearance (measured or calculated)\>45ml/min 4. Total bilirubin \<1.5 times upper limit of (institutional) normal 5. Aspartate Amino Transferase (AST) or Alanine Amino Transferase (ALT) \< three times the upper limit of (institutional) normal (if related to liver metastases \< five times ULN) 5. Eastern Cooperative Oncology Group (ECOG) score between 0-2 6. Written informed consent by patient or guardian prior to admission into the trial that is consistent with International Conference on Harmonization (ICH)- Good Clinical Practice (GCP) guidelines and local law 7. Recovery from any previous therapy related toxicity to \<=CTCAE Grade 1 at study entry (except for stable sensory neuropathy \<=CTCAE Grade 2 and alopecia)
Exclusion criteria
1. Prior treatment with an EGFR tyrosine kinase inhibitor (TKI) 2. Hormonal anti-cancer treatment within 2 weeks prior to start of trial treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted) 3. Radiotherapy within 28 days prior to drug administration, except as follows: 1. Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and 2. Single dose palliative treatment for symptomatic metastases outside above allowance to be discussed with sponsor prior to enrolling 4. Major surgery within 4 weeks before starting trial treatment or scheduled for surgery during the projected course of the trial 5. Known hypersensitivity to afatinib or any of its excipients 6. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to starting trial treatment 7. Women of Child-Bearing Potential (WOCBP) and men who are able to father a child, unwilling to use adequate contraception prior to trial entry, for the duration of trial participation and for at least 2 weeks after treatment has ended 8. Childbearing potential who: 1. are nursing or 2. are pregnant or 3. are not using an acceptable method of birth control, or do not plan to continue using this method throughout the trial and/or do not agree to submit to pregnancy testing required by this protocol 9. Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patients ability to comply with the trial or interfere with the evaluation of safety for the trial drug 10. Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured 11. Requiring treatment with any of the prohibited concomitant medications that cannot be stopped for the duration of trial participation 12. Known pre-existing interstitial lung disease 13. Presence of poorly controlled gastrointestinal disorders that could affect the absorption of the trial drug (e.g. Crohn's disease, ulcerative colitis, malabsorption, or Common Terminology Criteria grade =2 diarrhea of any aetiology) based on investigator assessment 14. Active hepatitis B infection (defined as presence of Hepatitis B (HepB) sAg and/or HepB DNA), active Hepatitis C (HEP C) infection (defined as presence of Hep C RNA) and/or known Human Immunodeficiency Virus (HIV) carrier 15. Meningeal carcinomatosis 16. Symptomatic brain metastases (patients with asymptomatic brain metastases, who were previously treated, are eligible provided they have had Stable Disease (SD) for at least 4 weeks on stable doses of corticosteroid)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety Assesment | From first administration of treatment until 28 days after last drug administration, up to 80 weeks. | Safety was assessed by: 1. All serious adverse events (SAEs) 2. All adverse events (AEs) leading to treatment discontinuation or dose reduction of afatinib 3. Non-serious AEs assessed by the treating physician as related to afatinib. |
Countries
Canada
Participant flow
Recruitment details
This open-label, multicenter, single-arm trial evaluated the safety & tolerability of the investigational drug afatinib.All entered patients in this trial (i.e., patients that had been treated with the trial medication) received continuous treatment of afatinib in the absence of disease progression or meeting any other trial withdrawal criteria.
Pre-assignment details
The planned trial end date was 10 February 2016. On the end date, all patients on treatment that met the approved label indication were planned to be switched to commercially available afatinib.
Participants by arm
| Arm | Count |
|---|---|
| Afatinib 40 mg Patient to receive a film coated tablet containing 40 mg afatinib once a day, with the option to reduce the dose to 30 or 20 mg/day, based on individual tolerability. | 14 |
| Total | 14 |
Baseline characteristics
| Characteristic | Afatinib 40 mg |
|---|---|
| Age, Continuous | 66.0 Years STANDARD_DEVIATION 10.8 |
| Sex: Female, Male Female | 7 Participants |
| Sex: Female, Male Male | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 14 / 14 |
| serious Total, serious adverse events | 3 / 14 |
Outcome results
Primary
Safety Assesment
Safety was assessed by: 1. All serious adverse events (SAEs) 2. All adverse events (AEs) leading to treatment discontinuation or dose reduction of afatinib 3. Non-serious AEs assessed by the treating physician as related to afatinib.
Time frame: From first administration of treatment until 28 days after last drug administration, up to 80 weeks.
Population: Treated set
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Afatinib 40 mg | Safety Assesment | Investigator defined drug-related AEs | 92.9 Percentage of participants |
| Afatinib 40 mg | Safety Assesment | AEs leading to dose reduction | 35.7 Percentage of participants |
| Afatinib 40 mg | Safety Assesment | AEs leading to discont. of trial drug | 35.7 Percentage of participants |
| Afatinib 40 mg | Safety Assesment | Serious AEs | 21.4 Percentage of participants |